Top 50 Biotechnology Startup Investors in United Kingdom (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
UK Innovation & Science Seed Fund
VC Fund
|
56 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
Parkwalk Advisors
VC Fund
|
44 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
Scottish Enterprise
VC Fund
|
43 | United Kingdom, United States, Japan | Seed, Grant | Biotechnology, Software, Health Care | $104k–$4.1M |
|
Oxford Science Enterprises
VC Fund
|
40 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
SOSV
VC Fund
|
37 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Oxford Technology Management
VC Fund
|
34 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$7.9M |
|
Jonathan Milner
Angel
|
30 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Catapult Ventures
VC Fund
|
29 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Medical | $150k–$26M |
|
Scottish Investment Bank
VC Fund
|
28 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Mercia Fund Managers
VC Fund
|
26 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
Development Bank of Wales
VC Fund
|
24 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
|
Epidarex Capital
VC Fund
|
23 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
Archangels
VC Fund
|
22 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $1.3M–$8.3M |
|
SFC Capital
VC Fund
|
22 | United Kingdom, United States, Canada | Pre-Seed, Seed | Software, Artificial Intelligence, Information Technology | $158k–$2.2M |
|
IP Group
VC Fund
|
21 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Sofinnova Partners
VC Fund
|
21 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
AlbionVC
VC Fund
|
20 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$20M |
|
Future Planet Capital
VC Fund
|
20 | United Kingdom, United States, Canada | Seed, Convertible Note | Biotechnology, Health Care, Software | $897k–$7.9M |
|
Wren Capital
VC Fund
|
19 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1.1M–$32M |
|
Northstar Ventures
VC Fund
|
19 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$9.7M |
|
Deepbridge Capital
VC Fund
|
19 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
GM&C Life Sciences Fund
VC Fund
|
18 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Oxford Capital
VC Fund
|
17 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Mobile | $1.5M–$16M |
|
Cambridge Innovation Capital
VC Fund
|
17 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$73M |
|
O2h Ventures
VC Fund
|
17 | United Kingdom, Hungary | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $655k–$26M |
|
TRICAPITAL
VC Fund
|
16 | United Kingdom, France | Seed, Series B | Biotechnology, Software, Health Care | |
|
Kelvin Capital
VC Fund
|
16 | United Kingdom, United States | Seed, Series A | Health Care, Biotechnology, Manufacturing | $144k–$25M |
|
Octopus Ventures
VC Fund
|
16 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.9M–$46M |
|
Syncona Partners LLP
VC Fund
|
16 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$131M |
|
Eos
VC Fund
|
15 | United Kingdom, Ireland, United States | Seed, Series A | Biotechnology, Health Care, Medical | $1.3M–$47M |
|
Hoxton Ventures
VC Fund
|
15 | United Kingdom, United States, Canada | Seed, Series A | Artificial Intelligence, Software, Information Technology | $1.8M–$29M |
|
M Ventures
VC Fund
|
14 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
IQ Capital
VC Fund
|
14 | United Kingdom, United States, Germany | Seed, Series A | Software, Artificial Intelligence, Machine Learning | $1.3M–$19M |
|
Kindred Capital
VC Fund
|
14 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
Newable Private Investing
VC Fund
|
14 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
Calculus Capital
VC Fund
|
14 | United Kingdom, United States, Ireland | Series A, Seed | Biotechnology, Software, Medical | $2M–$18M |
|
Business Growth Fund
VC Fund
|
13 | United Kingdom, Ireland, United States | Series A, Private Equity | Software, Health Care, Information Technology | $3M–$21M |
|
Cambridge Angels group
VC Fund
|
13 | United Kingdom, United States, Estonia | Seed, Series A | Software, Health Care, Biotechnology | $270k–$9.5M |
|
Nesta Ventures
VC Fund
|
13 | United Kingdom, United States | Seed, Series A | Biotechnology, Medical Device, Medical | $982k–$26M |
|
Par Equity
VC Fund
|
13 | United Kingdom, United States, Brazil | Series A, Seed | Software, Information Technology, Health Care | $380k–$14M |
|
YFM Equity Partners
VC Fund
|
12 | United Kingdom, United States, Belgium | Private Equity, Series A | Software, Information Technology, Biotechnology | $2.6M–$10M |
|
Clarendon Fund Managers
VC Fund
|
12 | United Kingdom, United States, Ireland | Seed, Pre-Seed | Software, Health Care, Biotechnology | $440k–$2.6M |
|
Wellcome Trust
VC Fund
|
12 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.3M–$127M |
|
Longwall Venture
VC Fund
|
12 | United Kingdom, Germany, Philippines | Seed, Series A | Biotechnology, Health Care, Medical Device | $637k–$16M |
|
SR One
VC Fund
|
12 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$115M |
|
F-Prime
VC Fund
|
12 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $9.2M–$130M |
|
Meltwind Advisory
VC Fund
|
11 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$26M |
|
Amadeus Capital Partners
VC Fund
|
11 | United Kingdom, United States, Spain | Series B, Seed, Series A | Software, Artificial Intelligence, Information Technology | $800k–$43M |
|
SIS Ventures
VC Fund
|
11 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1M–$19M |
|
24 Haymarket
VC Fund
|
11 | United Kingdom, United States | Seed, Series A | Health Care, Software, Information Technology | $714k–$16M |
| Access all 1704 investors in United Kingdom Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 130
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Presymptom Health — Enabling Early Diagnosis for better infection & sepsis care. With faster, more accurate testing. Presymptom Health is a medtech company developing a portfolio of patented diagnostic tests that are both faster and more reliable than those available today. Accelerate diagnosis. Address antimicrobial resistance.
- Pencil Biosciences — Pencil Biosciences is pioneering the next generation of gene editing. We are developing a fully synthetic, RNA-guided platform designed to overcome the limitations of current technologies.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 255
- Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Nozzle.ai — Award-winning Amazon analytics tools designed to provide FBA Amazon Sellers with unique customer insights. Try for Free.
- Phasecraft — Using disruptive theory to unlock the power of quantum computing
- Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Grant
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 286
- Round size: Seed $318k–$3.4M; Grant $104k–$4.1M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Moblyze — Moblyze is the first talent marketplace app for the energy transition.
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 161
- Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Mode Labs — Mode Labs provide robust, continuous, and remote real-time chemical sensors.
- Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
- Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 107
- Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 104
- Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Rinicare — Rinicare is Lancaster-based SME that offers innovative technology solutions for healthcare applications.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 133
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- 4D Medicine —
- Adludio — Adludio is the AI-powered platform that delivers interactive mobile advertising. By using data to design your ad creative, and algorithms to optimize your campaigns, Adludio makes sure you win the battle for brand attention.
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 211
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$2M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
- enModus — Experience the thrill of competing against other players in online casino tournaments! These events offer a unique opportunity to showcase your skills and
- Antiverse — Designing biologics for 100 challenging targets
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 47
- Round size: Seed $531k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$55M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Ryme Medical — Ryme Medical is a device company developing a novel catheter-based treatment for COPD
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 84
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- 1inhaler — 1inhaler operates as a developer of drug delivery device.
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 330
- Round size: Seed $159k–$2.2M; Pre-Seed $158k–$840k
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Elaitra — Elaitra’s breast cancer platform includes a Generative LLM for voice-based patient engagement, and a unique AI reading tool that helps doctors read 3D X-Rays. Operating in USA & UK. FDA 510(k) and UK regulator approved.
- Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
- WeFindFlats — Live and work anywhere, without housing worries.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 188
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Lumai — Lumai delivers optical compute for the inference era, enabling up to 50x AI performance and 90% less power. Supports billion-parameter LLMs today.
- AudioScenic — THE NEW DIMENSION IN SOUND
- Intrinsic Semiconductor Technologies — Exciting new developments around the Internet of Things, Big Data, autonomous vehicles, and Artificial Intelligence highlight how our approach to computation must fundamentally change.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 159
- Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Oviva — Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in London, England.
- uMotif — uMotif provides the most modern eCOA/ePRO and eConsent platform designed to power clinical and real-world research.
- Ophelos — Flexible repayments, with an empathetic approach. Discover how we can help you get debt-free on your terms and timescales.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 142
- Round size: Seed $897k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
- Vitarka Therapeutics — Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets.
Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 32
- Round size: Seed $1.1M–$5.2M; Series A $2M–$32M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
- MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 189
- Round size: Seed $39k–$1.8M; Series A $851k–$9.7M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- Moralbox —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 82
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 74% lead, 26% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
- GeneralPractice.AI — General Practice. AI is an advanced, AI-powered platform designed to transform primary care and general practice by streamlining clinical workflows, enhancing patient engagement, and reducing administrative burdens for healthcare professionals. It aims to revolutionize primary care by harnessing artificial intelligence to improve both clinical andadministrative aspects of general practice, ultimately delivering more efficient, personalized, and effective healthcare.
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Mobile
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 147
- Round size: Seed $1.5M–$3.9M; Series A $3.2M–$16M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $56M in 2015
Portfolio highlights
- eporta — eporta is Europe's leading B2B commerce platform for the furnishings industry, active in over 80 countries around the world.
- UltraSoC Technologies — UltraSoC Technologies is an independent provider of SoC infrastructure to enable rapid development of embedded systems based on advanced SoC devices. Its head office is in Cambridge and it has research and development labs in Colchester.
- Intent HQ — Intent builds AI that understands human intent. On-device processing. Zero personal data exported. 300M+ profiles. 49 patents.
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $3.9M–$23M; Series A $2M–$73M; Series B $8.5M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
- Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 39
- Round size: Seed $655k–$7.9M; Series A $1.9M–$26M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Neurocentrx — Neurocentrx is a specialty pharma company, developing and in-licensing products in pain, palliative care, psychiatry and mood disorders.
- Alevin Therapeutics — Our mission is to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies
The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series B
- Geography: United Kingdom, France
Investor stats
- Total investments: 49
- Lead/follow: no public data
Portfolio highlights
- HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
- Sellmyartworks — EzelDotz - Buy and Sell Contemporary Art Online | Art Marketplace. Curated collection of Sculptures, Limited Editions and Originals.
- Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality
Kelvin Capital was founded in 2009 and has since raised a total of over £50million into 28 portfolio companies. We invest venture capital in revenue generating growth companies which have the potential to deliver significant return to their investors. They also invest in companies that require capital to grow their business. For the right companywith the right team, Kelvin Capital provides the investment and the support needed to deliver the true potential of their business.The Kelvin Capital team has a combined 30 years experience of working with new businesses and understands both the challenges and opportunities, which will be encountered during the high growth phase. The team has built up extensive networks, which will be made available to assist and support the portfolio businesses. Kelvin Capital will actively promote the portfolio businesses through its website and social media activities raising their awareness and profile. The entire Kelvin Capital team is focused on the success of their portfolio of businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 79
- Round size: Seed $144k–$1.3M; Series A $1.7M–$25M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.
- Aurora Avionics — Accelerating launch-vehicle development with flexible and modular avionics platforms.
- Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 357
- Round size: Seed $1.9M–$11M; Series A $3M–$21M; Series B $7.5M–$46M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $101M in 2019
Portfolio highlights
- CertiVox — CertiVox solutions deliver simple, powerful information security to all things Internet (mainframes, too!), protecting business and individual privacy through the cloud and at rest. CertiVox was founded in 2009 to provide technology and services based on a simple belief: that everyone deserves the right to secure their information exchangessimply and easily. CertiVox's leading-edge encryption, key management and identity management solutions are currently in use at hundreds of the world’s leading corporations and used by individuals across the globe to protect their privacy.The companies passion is to create and share unique, cutting-edge cryptographic innovations for enterprise cloud computing and all things Internet. CertiVox are the only company in the global market today that has the technology in place to arm businesses and individuals with easy-to-use certificateless security solutions for any device and platform.Whether you are a business that wants to safeguard your company’s intellectual property, an ISV or SaaS provider that needs to embed cryptography and key management into your application, or an individual who wants to preserve the privacy of your personal data, CertiVox gives you the power to secure your information for all things Internet.CertiVox’s leading-edge solutions – including MIRACL (Multiprecision Integer and Rational Arithmetic C/C++ Library) Cryptographic SDK, on-demand encryption Key Management Service (KMS) and Identity Management Service (IDMS) – enable cloud service providers, independent software vendors (ISVs), communication providers, and smart device and semiconductor manufacturers to secure their voice and data communication solutions with ease.The PrivateSky Secure Information Exchange Service (SIX) gives individuals, businesses and their partners and customers easy-to-use tools to quickly encrypt email, files and documents without complex infrastructure or user burden. Compliance with mandatory encryption and privacy statues has never been easier.The bottom line: CertiVox's revolutionary certificateless cryptography, identity and key management solutions have taken the hassle out of Internet security, making it easy to securely exchange your information in any form, any time.
- Mojo — Join 600,000+ men worldwide using AI-powered coaches to build a performance mindset and take back control of their love lives.
- Phlux Technology — We develop, manufacture and supply innovative communication and vision components
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 50
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$131M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Apini Therapeutics — Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
- Purespring Therapeutics — A precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function.
Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 39
- Round size: Seed $1.3M–$6.1M; Series A $1.6M–$47M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- Neupulse — We are developing a wearable wrist device that delivers median nerve stimulation at the press of a button with the aim to give people control of their tics.
- Wobble Genomics — Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 128
- Round size: Seed $1.8M–$10M; Series A $5M–$29M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
- Malted AI — We create specialised intelligence that turns data into action, to power financial services of the future.
- Fabrica AI — Fabrica AI offers a revolutionary platform for faster robot development, using custom hardware designs and learned optimal control to increase efficiency while minimizing complexity and cost. With a vision for a future where robot development takes days, not years.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 183
- Round size: Seed $1.3M–$12M; Series A $4.5M–$19M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Molyon — Molyon is creating the next-generation energy storage system: the lithium-sulfer battery. Molyon offers long-life lithium-sulfur batteries that have twice the energy density of existing lithium-ion batteries on the market.
- Nyobolt — Nyobolt develops high-power energy storage systems based on advanced lithium-ion battery technology designed for rapid charging and sustained high performance. The company focuses on battery systems that enable very fast energy replenishment, supporting applications where downtime needs to be minimized. Its technology combines specialized anodematerials, cell design, battery management systems, and power electronics to achieve high charge and discharge rates. The platform is used in sectors such as robotics, data centers, industrial equipment, and electric mobility where consistent high power delivery is required. It also develops integrated energy solutions that support demanding workloads like automated logistics systems and high-performance computing infrastructure. Nyobolt’s approach emphasizes optimizing cycle life, thermal stability, and energy density for repeated fast charging environments.
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 108
- Round size: Seed $1.5M–$16M; Series A $7.9M–$33M; Series B $13M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Hofy — Use Hofy's equipment management platform to remotely supply, manage and maintain subscription workstations, while staying compliant.
- RobCo — Easily automate the repetitive tasks in your production facility with modular industrial robots from RobCo.
- Paddle — The revenue engine powering payments for n8n, Letterboxd & AdGuard. One platform that handles subscription billing, payments and compliance.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Elemendar — Elemendar is building Artificial Intelligence that reads cyber threat reports by humans and turns them into industry-standard structured information.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Series A, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 71
- Round size: Seed $2M–$18M; Series A $2.6M–$9.2M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- EnsiliTech — EnsiliTech is a biotechnology start-up developing ensilication, a platform technology, to remove the need for refrigeration when transporting and storing vaccines and biologicals
- Grateful — Grateful provides cashless tipping and trunk management software that integrates QR/NFC, EPOS systems, and compliance reporting.
- Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Private Equity
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 292
- Round size: Series A $3M–$21M; Private Equity $6.5M–$20M
- Lead/follow: 83% lead, 17% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Camino — Camino Leisure Holdings is a Spanish bar and restaurant that serves authentic food and wines.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
- Snipple Animation Studios — Snipple are specialists in animated television and sports entertainment. We are one of the largest animation partners to Disney and Warner Brothers. We develop original IP and we have unique partnerships with sports teams, growing the fans of the future.
The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Estonia
Investor stats
- Total investments: 130
- Round size: Seed $270k–$2.9M; Series A $2M–$9.5M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- FLIT — Unfold Your Next Adventure. Discover the compact folding electric bike purpose-built for commuters, urban explorers and weekend tourers.
- Wilder Sensing — Wilder Sensing analyses audio and other data sources to produce actionable insights into the status and trends of biodiversity on your site.
- AVIEL Intelligence — Prevent APP fraud with the highest quality of intelligence. Use AVIEL intelligence to help prevent your customers making payments to scammers - and from receiving payments related to scams.
We bring bold ideas to life to change the world for good.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 72
- Round size: Seed $982k–$2.2M; Series A $1.5M–$26M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $34M in 2014
Portfolio highlights
- Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
- Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
- Radio Physics Solutions — PASAR123 merupakan landasan utama bandar slot nomor 1 di indonesia memiliki fasilitas slot deposit pulsa tanpa potongan penarikan sangat mudah dan cepat.
Founded in 2008, Par Equity is a venture capital firm that backs the most innovative, high growth technology companies in the North of the UK. Based in Edinburgh, Par invests across Northern England, Northern Ireland and Scotland.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, Brazil
Investor stats
- Total investments: 189
- Round size: Seed $380k–$8M; Series A $1.7M–$14M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
- Manus Neurodynamica — Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!YFM Equity Partners is an independent private equity business owned by its senior management and investment team. They invest up to £10 million of equity through offices in Leeds, London, Manchester, Birmingham and Sheffield.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Private Equity, Series A
- Geography: United Kingdom, United States, Belgium
Investor stats
- Total investments: 111
- Round size: Series A $4.7M–$10M; Private Equity $2.6M–$10M
- Lead/follow: 75% lead, 25% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Workbuzz — Workbuzz is a professional network that allows you to anonymously research, rate and review your peers in the workplace.
- Unbiased — Unbiased connects millions of people with professional advice. With a mission to deliver the perfect adviser match with zero stress, it has developed the UK’s most powerful search tools for connecting consumers with the widest available choice of advisers. To date the site has connected over 10 million people with professional advice.The sitelists over 24,000 IFAs, financial advisers, mortgage advisers and accountants, and between them Unbiased’s advisers manage at least £14 billion worth of assets. Consumers searching on Unbiased can refine their search by area of expertise, gender, payment options, advice areas, level of wealth, qualifications, accreditations and more. Alternatively, they can be matched automatically with the best local adviser, usually within 48 hours and often within 6.The Unbiased site also maintains a constant stream of consumer-focused content, alongside innovative tools, a live ask-an-adviser forum and a comprehensive range of money management information.Unbiased's headquarters form part of London’s expanding Tech City, the biggest tech cluster in Europe.
- Quality Clouds — Quality Clouds is the only platform that provides independent, continuous governance across ServiceNow, Salesforce and AI-native platforms. Catch issues before they reach production. Trusted by Barclays, BASF and more.
We ensure that businesses in Northern Ireland with growth aspirations can access equity finance to reach their potential.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 68
- Round size: Seed $440k–$2.6M; Pre-Seed $735k–$1.5M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $17M in 2003
Portfolio highlights
- Cirdan — Cirdan provides highly reliable, innovative LIS & imaging solutions for the acceleration & enhancement of diagnosis, optimized for pathology & clinical lab.
- PathXL — Cirdan provides highly reliable, innovative LIS & imaging solutions for the acceleration & enhancement of diagnosis, optimized for pathology & clinical lab.
- LifeCellsNI — LifeCellsNI is committed to offering families and people throughout Northern Ireland and Ireland state-of-the-art stem cell extraction and storage services.
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 115
- Round size: Grant $1.3M–$8M; Series C $10M–$127M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $319M in 2018
Portfolio highlights
- Cultivarium — We develop molecular, hardware and software tools to accelerate the adoption of microbes for beneficial biotechnologies.
- Lario Therapeutics — Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders.
- Ineffable Intelligence — Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains.
Longwall Ventures invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical Device
- Stage:Seed, Series A
- Geography: United Kingdom, Germany, Philippines
Investor stats
- Total investments: 46
- Round size: Seed $637k–$5.6M; Series A $2.4M–$16M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $101M in 2017
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- Kinomica — Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage.
- Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 182
- Round size: Series A $3.7M–$87M; Series B $15M–$114M; Series C $22M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
- Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 410
- Round size: Series A $9.2M–$87M; Series B $16M–$130M; Series C $22M–$115M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- SILQ — Bringing visibility to brands by customizing sourcing and shipping on everything that you need for your business.
- Deal Engine — Deal Engine is a travel solutions software company that reduces corporate travel expenditure ensuring saving on a flight itinerary.
- RightHand Robotics — RightHand Robotics offers advanced robotic piece-picking technology for efficient and predictable order fulfillment. Contact us today to learn how.
Meltwind Advisory.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 27
- Round size: Seed $1.3M–$17M; Series A $2.8M–$26M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Syndex Bio —
- Enhanc3D Genomics — Enhanc3D Genomics is a spinout company from Babraham Institute.
- Axol Bioscience — Home AXOL Bioscience Axol Bioscience, focussed on the supply of human iPSC derived cells for research and drug discovery. Cardiomyocytes and neuronal cells.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series B, Seed, Series A
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 230
- Round size: Seed $800k–$9.2M; Series A $2.6M–$27M; Series B $6.8M–$43M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $88M in 2023
Portfolio highlights
- Tenzo — Tenzo is a restaurant analytics and AI forecasting platform for restaurants, pubs and cafes. Tenzo makes running restaurants easy with full data visibility.
- Xampla — Xampla's natural plant polymer technology is the innovative technology powering materials to change the world with plastic-free replacements and more.
- Nu Quantum — Nu Quantum has been pioneering quantum networking technology since 2018. Our market-leading expertise is uniquely positioned to deliver a distributed quantum...
SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 33
- Round size: Seed $1M–$5.2M; Series A $2.8M–$19M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $1M in 2018
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 100
- Round size: Seed $714k–$3.8M; Series A $1.6M–$16M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Angoka — ANGOKA is an IoT security company focused on protecting M2M communications for Smart Cities and Mobility. Headquartered in Belfast, with offices in London and The Hague, ANGOKA offers solutions that protect devices’ identities. With an increase of inherently insecure networks coming online with the boom of IoT, ANGOKA’s solutions safeguard criticalmachine-to-machine communication integrity and data provenance, creating trusted connections, even in untrustworthy networks.ANGOKA is the only cybersecurity company to win a place on Zenzic’s CAM Scale-Up Programme, delivered in partnership with Plug and Play. ANGOKA was also the first NI start-up to be selected for NCSC’s Cyber Accelerator, who reviewed and assessed ANGOKA’s technology. ANGOKA is also an alumnus of Seraphim Space Camp, Yes!Delft and TechNation Cyber 2.0. Finally, ANGOKA has been awarded several Innovate UK R&D projects, which focus on securing quantum communications (led by BT) and two drone projects.
- CyberOwl — CyberOwl develops an innovative early warning system for attacks through real-time monitoring of high-value targets for malicious behavior. The technology, based on research shortlisted for the Lloyd’s Science of Risk Prize 2015, is aimed at addressing the challenges of increasingly anonymous and persistent threats to rapidly-expanding globalnetworks, particularly in the wake of Smart Cities and the Internet of Things. The system raises early warning on network assets for possible undesirable activity, by applying a Bayesian-based framework to systematically analyze indicators associated with early stages of such activity. This approach dramatically reduces the processing overheads of monitoring. The benefits to the security operation include scalability to networks exceeding 1 billion devices, providing earlier visibility of risk and improving prioritization and decision-making in deploying countermeasures. CyberOwl is developing its minimum viable product and is looking for two or three strategic industry design partners for validation, verification, and further development. The ideal design partner would provide access to real-world security problems in a large network, high-volume data environment.CyberOwl was founded on 2016 and is headquartered in London, England.
- Kelda Technology — Kelda Technology is a British clean tech business that develops water-in-air shower products that halve water usage and water heating costs through patented shower technology. Kelda Technology has adapted cutting edge automotive and aerospace technology to produce a revolutionary “water-in-air” shower system that halves water use without any lossin performance. Water is broken into droplets to form a comfortable spray which is accelerated using a globally patented jet-type nozzle. Not only does it halve water costs, but also halves associated heating costs.The Kelda shower system holds appeal for a wide range of sectors, including gym and leisure, hotels and accommodation providers, healthcare, and maritime – all industries where water efficiency is key. The product has completed in-market validation and commercial trials, is in manufacture and the company has already signed installation deals with some of the largest leisure operators in the UK and Latin America.Kelda Technology was recently chosen as one of the top 30 cleantech companies in the world at the New Energy Start-Up awards 2016 and was this week shortlisted by the UK Business Angels Association for Best Investment in a Disruptive Tech Business.
Biotechnology Investor funding in United Kingdom at a glance
Stats across 2.1k deals from 1.7k investors.
Access all 1704 investors in United Kingdom Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1704 investors investing in United Kingdom Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!